Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

34.19USD
10:40am EST
Change (% chg)

$-0.28 (-0.81%)
Prev Close
$34.47
Open
$34.27
Day's High
$34.46
Day's Low
$34.11
Volume
1,063,397
Avg. Vol
7,722,235
52-wk High
$34.96
52-wk Low
$27.51

PFE.N

Chart for PFE.N

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.76
Market Cap(Mil.): $218,380.80
Shares Outstanding(Mil.): 6,300.66
Dividend: 0.28
Yield (%): 3.23

Financials

  PFE.N Industry Sector
P/E (TTM): 24.45 38.98 40.20
EPS (TTM): 1.42 -- --
ROI: -- 17.01 16.34
ROE: -- 17.52 17.27
Search Stocks

Copy me: Europe shows U.S. a path to cheaper biotech drugs

LONDON/LOS ANGELES - A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe.

2:05am EST

INSIGHT-Copy me: Europe shows U.S. a path to cheaper biotech drugs

LONDON/LOS ANGELES, March 6 - A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe.

2:00am EST

MOVES-Guggenheim hires healthcare bankers from JPMorgan, BofA - WSJ

March 3 - Guggenheim Partners has hired Jeff Hoffman and Joseph Kohls as senior managing directors to bolster its healthcare investment banking team, the Wall Street Journal reported.

03 Mar 2015

UPDATE 1-Sanofi's new boss could earn more than Total's, less than Pfizer's

PARIS, Feb 20 - Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros ($4.8 million) a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake.

20 Feb 2015

REFILE-US STOCKS-Wall St rises on Greek deal hopes even as energy drops

NEW YORK, Feb 10 - U.S. stocks rose on Tuesday on hopes that Greek debt negotiations could result in a deal that stabilizes Europe although a drop in oil prices limited the advance.

10 Feb 2015

Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co

- Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

09 Feb 2015

Pfizer in $5 bln accelerated buyback deal with Goldman, Sachs & Co

Feb 9 - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

09 Feb 2015

Fitch Affirms Pfizer's IDR at 'A+'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, February 06 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s (Pfizer's) ratings, including the 'A+' Issuer Default Rating (IDR). The rating action follows Pfizer's announcement that it will acquire Hospira, Inc. (HSP) for roughly $17 billion which includes approximately $1.7 billion in HSP debt. The rating action applies to approximately $38.9 billion of consolidated debt outstanding as of Sept. 28, 2014. The Rating Outloo

06 Feb 2015

RPT-Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

06 Feb 2015

Pfizer to buy Hospira for $15 billion to bolster hospital products

By Caroline Humer, Ransdell Pierson, Vidya L Nathan and Natalie Grover | Video

05 Feb 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.27 -1.25
Novartis AG (NOVN.VX) CHF96.60 +0.30
Merck & Co., Inc. (MRK.N) $57.42 -0.56
Roche Holding Ltd. (ROG.VX) CHF261.30 +5.20
Abbott Laboratories (ABT.N) $46.94 -0.50
Bayer AG (BAYGn.DE) €134.30 +0.95
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.89 +0.05
AstraZeneca plc (AZN.L) 4,435.00p -51.50
GlaxoSmithKline plc (GSK.L) 1,567.00p -4.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks